Role of tyrosine kinase inhibitors in the management of philadelphia chromosome-positive acute lymphoblastic leukemia

Current Hematologic Malignancy Reports

Volumn 6, Issue 3, 2011, Pages 187-194

  Mathisen, Michael S ^a   O'Brien, Susan ^a   Thomas, Deborah ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute lymphoblastic leukemia; ALL; Chemotherapy; Complications; Dasatinib; Imatinib; Ph+ ALL; Philadelphia chromosome; Stem cell transplantation; Therapy; Treatment; Tyrosine kinase inhibitors

Indexed keywords

BAFETINIB; BCR ABL PROTEIN; BOSUTINIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DCC 2036; DEXAMETHASONE; DOXORUBICIN; IMATINIB; METHOTREXATE; NILOTINIB; PONATINIB; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; TACROLIMUS; UNCLASSIFIED DRUG; VINCRISTINE; XL 228;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME INHIBITION; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; INTRACELLULAR SIGNALING; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LONG TERM CARE; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MORTALITY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATITIS; PATIENT PREFERENCE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PROBABILITY; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; SALVAGE THERAPY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FUSION PROTEINS, BCR-ABL; HUMANS; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; STEM CELL TRANSPLANTATION; THIAZOLES; TRANSPLANTATION, HOMOLOGOUS;

EID: 80055063164     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0093-y     Document Type: Article

References (54)

1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-3.
2. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood. 1999;93:3983-93. (Pubitemid 29249848)
3. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357-66.
4. Faderl S, Kantarjian HM, Thomas DA, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000;36:263-73. (Pubitemid 30060177)
5. Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the international ALL trial MRC UKALLXII/ECOG2993. Blood. 2009;113:4489-96.
6. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460-6. (Pubitemid 46630465)
7. Hatta Y, Mizuta S, Ohtake S, et al. Promising outcome of imatinibcombined chemotherapy followed by allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the Japan Adult Leukemia Study Group (JALSG) Ph+ALL202 regimen [abstract]. Blood (ASH Annual Meeting Abstracts) 2009;114. Abstract 3090.
8. Kantarjian HM, Cortes J, La Rosee P, et al. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer. 2010;116:1419-30.
9. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054-61.
10. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-42. (Pubitemid 32267973)
11. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100:1965-71. (Pubitemid 35001224)
12. Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001;97:1999-2007. (Pubitemid 32239079)
13. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with hyper- CVAD and imatinib mesylate. Blood. 2004;103:4396-407. (Pubitemid 38745962)
14. Thomas DA, O'Brien SM, Faderl S, et al. Long-term outcome after hyper-CVA and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) [abstract]. J Clin Oncol. 2010;28:15s. Abstract 6506.
15. Tanguy-Schmidt A, de Labarthe A, Rousselot P, et al. Long-term results of the imatinib GRAAPH-2003 study in newly-diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2009;114. Abstract 3080.
16. Ribera J-M, Oriol A, Gonzalez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010;95:87-95.
17. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28:3644-52.
18. Fang G, Kim CN, Perkins CL, et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes BCR-ABLpositive human leukemia cells to apoptosis due to antileukemia drugs. Blood. 2000;96:2246-53.
19. Pfeifer H, Goekbuget N, Volp C, et al. Long-term outcome of 335 patients receiving different schedules of imatinib and chemotherapy as front-line treatment for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2010;116. Abstract 173.
20. Fielding AK, Buck G, Lazarus HM, et al.: Imatinib significantly enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia; final results of the UKALLXII/ ECOG2993 trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2010, 116:Abstract 169.
21. Schultz K, Bowman W, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol. 2009;27:5175-81.
22. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006;108:1469-77. (Pubitemid 44316110)
23. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010;7-12.
24. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:2730-41.
25. Pane F, Cimino G, Izzo B, et al. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2005;19:628-35. (Pubitemid 40521168)
26. Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to post-transplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2005;106:458-63. (Pubitemid 40981238)
27. Lee S, Kim DW, Cho B, et al. Risk factors for adults with Philadelphia-chromosome positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol. 2003;120:145-53. (Pubitemid 36056923)
28. Yanada M, Sugiura I, Takeuchi J, et al. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphiachromosome positive acute lymphoblastic leukaemia undergoing imatinib-containing chemotherapy. Br J Haematol. 2008;143:503-10.
29. Ravandi F, Thomas DA, O'Brien S, et al. Dynamics of minimal residual leukemia after combinations of the hyperCVAD regimen with imatinib or dasatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2010;116. Abstract 2127.
30. Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph- adult acute lymphoblastic leukemia. The Polish Adult Leukemia Group ALL-4-2002 MRD Study. Br J Haematol. 2008;142:227-37. (Pubitemid 351994055)
31. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase II study. Blood. 2007;110:2309-15. (Pubitemid 47523149)
32. Jones D, Thomas D, Yin CC, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008;113:985-94.
33. Soverini S, Vitale A, Poerio A, et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica. 2011;96:552-7.
34. Hu Y, Liu Y, Pelletier S, et al. Requirement of SRC kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004;36:453-61. (Pubitemid 38620028)
35. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401. (Pubitemid 38938156)
36. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-41. (Pubitemid 43882349)
37. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood. 2009;114:5426-35.
38. Lilly MB, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase III study. Am J Hematol. 2010;85:164-70.
39. Sprycel (dasatinib) Package Insert. Princeton, NJ. Bristol-Myers- Squibb Company. October 2010.
40. Ravandi F, O'Brien S, Thomas D, et al. First report of phase II study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010;116:2070-7. This is the first report with sufficient follow-up data describing the combination of a second-generation tyrosine kinase inhibitor with intensive chemotherapy for Ph+ ALL.
41. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129-41. (Pubitemid 40248339)
42. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-51. (Pubitemid 43882350)
43. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-9.
44. Kang BW, Moon JH, Chae YS, et al. Pre-emptive treatment with nilotinib after second allogeneic transplantation in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient with high risk of relapse. Acta Haematol. 2010;123:242-7.
45. Castillo E, Al-Rajabi R, Pandya DM, et al. A pilot study of the combination of nilotinib and hyper-CVAD for Philadelphia chromosome-positive acute lymphocytic leukemia and lymphoid blast crisis chronic myelogenous leukemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2010;116. Abstract 2144.
46. Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood. 2009;114:2168-71.
47. Ravandi F, Kebriaei P. Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin N Am. 2009;23:1043-63.
48. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCRABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401-12.
49. Cortes J, Talpaz M, Bixby D, et al. A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myeloid leukemia (CML) and other hematological malignancies: emerging safety and clinical response findings [abstract]. Blood (ASH Annual Meeting Abstracts) 2010;116. Abstract 210.
50. Dombret H, Gabert J, Boiron MJ, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357-66.
51. Thomas DA. Philadelphia chromosome-positive acute lymphoblastic leukemia: a new era of challenges. Hematology Am Soc Hematol Educ Program. 2007;435-43.
52. Mizuta S, Matsuo K, Yagasaki F, et al. Pre-transplant imatinibbased therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia. 2011;25:41-7.
53. Anderlini P, Sheth S, Hicks K, et al. Re: imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Tr. 2004;10:883-4. (Pubitemid 39625310)
54. Wassmann B, Pfeifer H, Bethge W, et al. Up-front versus minimal residual disease triggered imatinib after stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia; interim results of a randomized phase III GMALL study. Bone Marrow Transpl. 2009;43 suppl 1:S48.